The Munich-based biotech start-up RNhale has received funding as part of the European Innovation Council (EIC) Transition Programme. This makes RNhale one of the 40 innovative projects that the EIC is funding on their way from research to market maturity.
RNhale is developing RNAi-based therapeutics for the treatment of respiratory diseases and was founded in 2023 as a spin-off from Ludwig-Maximilians-Universität München. The EIC funding will enable the start-up to further develop its technologies and accelerate the path to clinical application. With its platform technology for the formulation of RNA-loaded lipid nanoparticles (LNPs), RNhale aims to develop these as an inhalable dry powder. Specifically, RNhale plans to use the funding to bring its asthma lead product to clinical maturity.
The funding from the EIC Transition Programm is devoted to maturing the technologies and build a business case for specific applications. Grants are available to validate and demonstrate technology in application-relevant environment and develop market readiness.
More information: European Innovation Council News